Table 2.
Descriptive Immunogenicity Based on HI Antibody Titers in the per Protocol Cohort for Immunogenicity
| N | Vaccine strain |
||||||
|---|---|---|---|---|---|---|---|
| A/California/7/2009 (H1N1) | A/Victoria/210/2009 (H3N2) | B/Brisbane/60/2008 (Victoria) | B/Brisbane/3/2007 (Yamagata) | ||||
| GMT, Value (95% CI) | QIV | Pre | 790 | 21.6 (19.7–23.7) | 29.0 (26.6–31.6) | 30.9 (28.2–33.9) | 77.3 (70.0–85.3) |
| Post | 791 | 386.2 (357.3–417.4) | 228.8 (215.0–243.4) | 244.2 (227.5–62.1) | 569.6 (533.6–608.1) | ||
| TIV-Vic | Pre | 819 | 24.9 (22.8–27.3) | 31.4 (28.8–34.2) | 31.0 (28.2–34.0) | 77.2 (70.0–85.2) | |
| Post | 818 | 433.2 (401.0–468.0) | 227.3 (213.3–242.3) | 245.6 (229.2–263.2) | 224.7 (207.9–242.9) | ||
| TIV-Yam | Pre | 800 | 22.1 (20.1–24.2) | 31.2 (28.6–34.2) | 33.2 (30.2–36.6) | 84.7 (76.6–93.6) | |
| Post | 801 | 422.3 (390.5–456.5) | 234.0 (219.1–249.9) | 88.4 (81.5–95.8) | 643.3 (603.2–686.1) | ||
| QIV (6–35 m) | Pre | 232 | 12.3 (10.2–14.8) | 8.6 (7.4–9.9) | 9.0 (7.9–10.4) | 13.1 (11.4–15.2) | |
| Post | 234 | 140.0 (113.7–172.3) | 87.5 (73.8–103.7) | 86.4 (72.6–102.9) | 167.7 (144.1–195.3) | ||
| SPR, % (95% CI) | QIV | Pre | 790 | 43.4 (39.9–47.0) | 48.2 (44.7–51.8) | 48.2 (44.7–51.8) | 71.5 (68.2–74.6) |
| Post | 791 | 96.6 (95.1–97.7) | 98.0 (96.7–98.8) | 97.3 (96.0–98.3) | 99.2 (98.4–99.7) | ||
| TIV-Vic | Pre | 819 | 49.3 (45.9–52.8) | 50.3 (46.8–53.8) | 48.4 (44.9–51.8) | 70.2 (66.9–73.3) | |
| Post | 818 | 96.9 (95.5–98.0) | 97.8 (96.5–98.7) | 96.6 (95.1–97.7) | 94.4 (92.6–95.9) | ||
| TIV-Yam | Pre | 800 | 44.1 (40.6–47.6) | 51.1 (47.6–54.6) | 49.9 (46.4–53.4) | 74.1 (70.9–77.1) | |
| Post | 801 | 97.1 (95.7–98.2) | 96.5 (95.0–97.7) | 79.8 (76.8–82.5) | 99.6 (98.9–99.9) | ||
| QIV (6–35 m) | Pre | 232 | 25.9 (20.4–32.0) | 14.7 (10.4–19.9) | 12.1 (8.2–17.0) | 20.7 (15.7–26.5) | |
| Post | 234 | 79.9 (74.2–84.9) | 72.2 (66.0–77.9) | 71.4 (65.1–77.1) | 90.6 (86.1–94.0) | ||
| SCR, % (95% CI) | QIV | Post | 790 | 91.4 (89.2–93.3) | 72.3 (69.0–75.4) | 70.0 (66.7–73.2) | 72.5 (69.3–75.6) |
| TIV-Vic | Post | 818 | 89.9 (87.6–91.8) | 70.7 (67.4–73.8) | 68.5 (65.2–71.6) | 37.0 (33.7–40.5) | |
| TIV-Yam | Post | 800 | 91.6 (89.5–93.5) | 71.9 (68.6–75.0) | 29.6 (26.5–32.9) | 70.8 (67.5–73.9) | |
| QIV (6–35 m) | Post | 232 | 78.0 (72.1–83.2) | 68.5 (62.1–74.5) | 68.1 (61.7–74.1) | 82.3 (76.8–87.0) | |
| SCF, value (% CI) | QIV | Post | 790 | 18.0 (16.6–19.5) | 7.9 (7.3–8.6) | 7.9 (7.3–8.6) | 7.4 (6.8–8.0) |
| TIV-Vic | Post | 818 | 17.4 (16.0–18.8) | 7.2 (6.7–7.8) | 7.9 (7.2–8.6) | 2.9 (2.7–3.1) | |
| TIV-Yam | Post | 800 | 19.2 (17.7–20.9) | 7.5 (6.9–8.1) | 2.7 (2.5–2.9) | 7.6 (7.0–8.3) | |
| QIV (6–35 m) | Post | 232 | 11.7 (10.2–13.4) | 10.4 (9.0–11.9) | 9.7 (8.5–11.2) | 12.9 (11.0–15.3) | |
SPR defined as proportion of subjects with HI antibody titers ≥1:40; SCR defined as proportion of subjects with a prevaccination HI antibody titer <1:10 and postvaccination HI antibody titer ≥1:40, or subjects with at least a 4-fold increase in the postvaccination HI antibody titer; SCF defined as the geometric mean of the within subject ratios of reciprocal HI antibody titers for postvaccination vs prevaccination.
Abbreviations: CI, confidence interval; GMT, geometric mean titer; HI, hemagglutination-inhibition; M, months; QIV, quadrivalent inactivated influenza vaccine; SCF, seroconversion factor; SCR, seroconversion rate; SPR, seroprotection rate; TIV-Vic, trivalent inactivated influenza vaccine Victoria lineage B strain; TIV-Yam, trivalent inactivated vaccine Yamagata lineage B strain.